

## REMARKS

### Claim Amendments

Applicants cancel claims 39, 40 and 41 herein without prejudice or disclaimer. Applicants expressly reserve the right to prosecute canceled claims, or claims based on the subject matter of canceled claims, in other applications, such as divisional applications or continuation applications.

Claims 11, 22, and 49 are amended herein. Claims 99 and 100 are newly added. The claim amendments and new claims are to more particularly claim certain embodiments of the invention.

Support for the amendments to claim 11, 22, and 49 is found throughout the application, for example, at least in paragraph [0129] on page 55 of the application as filed. Support for new claims 99 and 100 can be found, for example, at least in paragraphs [0178] (page 72) and [0186] (page 75) of the application as filed.

The claim amendments and new claims introduce no new matter, and their entry is respectfully requested.

### Restriction Requirement

In response to the Restriction Requirement of August 21, 2007, Applicants elect Group II, drawn to a modified Ter-binding protein. Regarding species elections, Applicants elect a label for the protein modification species; Applicants elect *Yersinia pestis* Ter binding protein (SEQ ID NO: 79) for the Ter-binding protein; and Applicants elect a filter or membrane for the support.

Claims newly presented in the present amendment are drawn to a Ter-binding protein bound to a solid support, and depend from claims 21 and 48, which are within elected Group II. These claims more particularly claim certain embodiments of the invention, and are within the subject matter of Group II as delineated by the Examiner in the Restriction Requirement. Applicants therefore respectfully request that the Examiner enter the amendment and Applicants' response to Restriction Requirement with the

elected claims of Group II to include claims 10-15, 20-22, and 47-52, and newly presented claims 99 and 100.

Conclusion

Applicant believes that a full and complete reply has been made to the outstanding Restriction Requirement. If the Examiner believes, for any reason, that personal communication will expedite prosecution of this application, the Examiner is invited to telephone the undersigned at the number provided.

Prompt and favorable consideration of this Amendment and Reply is respectfully requested.

Respectfully submitted,

/Emanuel J. Vacchiano/

Emanuel J. Vacchiano, Registration number 43,964

Invitrogen Corporation

Customer No. 52059

(760) 476-7055

November 21, 2007